Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O95905: Variant p.Asn501Ser

Protein ecdysoneless homolog
Gene: ECD
Feedback?
Variant information Variant position: help 501 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Asparagine (N) to Serine (S) at position 501 (N501S, p.Asn501Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (N) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 501 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 644 The length of the canonical sequence.
Location on the sequence: help ITFDADSFLNYFDKILGPRP N ESDSDDLDDEDFECLDSDDD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         ITFDAD-----------SFLNYFDKILGPRP--NESDSDDLD-DEDFECLDSDDD

Mouse                         ITFDAD-----------SFLNYFDKILGAKP--QESDSEDD

Drosophila                    PQANGSTGLTAKVKKNPSMRKACQRNSVIQP--EEPDSTHV

Slime mold                    YGNGGDDNISFDSNKFMDILKGFTDNNKYDDDYDDDDDDDD

Fission yeast                 YGVKNS-----------------DTDTDSDSLADSDDEIFL

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 644 Protein ecdysoneless homolog
Region 439 – 644 Transcription activation
Region 496 – 537 Disordered
Modified residue 503 – 503 Phosphoserine
Modified residue 505 – 505 Phosphoserine
Modified residue 518 – 518 Phosphoserine
Mutagenesis 481 – 481 I -> A. Decreases transactivation activity.
Mutagenesis 484 – 484 D -> F. Decreases transactivation activity.
Mutagenesis 489 – 489 L -> A. Decreases transactivation activity.
Mutagenesis 503 – 503 S -> A. Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-505, A-518, A-572, A-579 and A-584.
Mutagenesis 505 – 505 S -> A. Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-518, A-572, A-579 and A-584.
Mutagenesis 510 – 510 D -> R. Increases transactivation activity.
Mutagenesis 512 – 512 D -> R. Increases transactivation activity.
Mutagenesis 518 – 518 S -> A. Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-505, A-572, A-579 and A-584.
Mutagenesis 520 – 520 D -> P. Increases transactivation activity.



Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.